	US 11,717,504 B2
	Methods of reducing the risk of cardiovascular events in a subject
Paresh Soni, Mystic, CT (US)
Assigned to Amarin Pharmaceuticals Ireland Limited, Dublin (IE)
Filed by Amarin Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Dec. 18, 2020, as Appl. No. 17/126,619.
Application 17/126,619 is a continuation of application No. 16/927,224, filed on Jul. 13, 2020, granted, now 11,000,499.
Application 16/927,224 is a continuation of application No. 16/736,936, filed on Jan. 8, 2020, granted, now 10,786,478.
Application 16/736,936 is a continuation of application No. 16/574,415, filed on Sep. 18, 2019, abandoned.
Application 16/574,415 is a continuation of application No. 16/391,128, filed on Apr. 22, 2019, granted, now 10,668,042, issued on Jun. 2, 2020.
Claims priority of provisional application 62/818,514, filed on Mar. 14, 2019.
Claims priority of provisional application 62/813,888, filed on Mar. 5, 2019.
Claims priority of provisional application 62/758,387, filed on Nov. 9, 2018.
Claims priority of provisional application 62/735,680, filed on Sep. 24, 2018.
Claims priority of provisional application 62/735,670, filed on Sep. 24, 2018.
Prior Publication US 2021/0100768 A1, Apr. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/232 (2006.01); A61P 9/10 (2006.01); A61K 9/00 (2006.01); A61K 31/40 (2006.01); A61K 31/505 (2006.01)

CPC A61K 31/232 (2013.01) [A61K 9/0053 (2013.01); A61P 9/10 (2018.01); A61K 31/40 (2013.01); A61K 31/505 (2013.01)]

20 Claims

1. A method of reducing an incidence of stroke in a subject with triglyceride levels of greater than 150 mg/dL, the method comprising administering to the subject about 4 g of ethyl icosapentate daily, wherein the subject experiences atrial fibrillation and/or flutter instead of an incidence of stroke after the administration.